Predicting REsponses to chemotherapy from NUTRition In Triple NegatIVE Breast Cancer: The PRE-NUTRITIVE Study.

niversity of Leeds0 个研究点目标入组 20 人开始时间: 2022年12月12日最近更新: 2024年9月2日

适应症

试验速览

暂无简介。

•Current participant inclusion criteria as of 21/08/2024:
•1. Patients aged 18 years or older
•2. Uni or bilateral TNBC in the breast and/or axilla (including primary, second primary, locoregional recurrence, or inflammatory breast cancer)
•3. Clinical recommendation for NACT
•4. Ability to provide informed consent
•5. Uni- or multi-focal invasive breast cancer of any histological subtype (if multifocal, dominant lesion that is triple negative to be biopsied) and any tumour (T) and clinical node (N) staging.
•Previous participant inclusion criteria:
•1. Patients aged 18 years or older
•2. Newly diagnosed uni- or bilateral TNBC in the breast and/or axilla
•3. Clinical recommendation for NACT
•4. Ability to provide informed consent
•5. Uni- or multi-focal invasive breast cancer of any histological subtype (if multifocal, dominant lesion that is triple negative to be biopsied)
•6. Tumour staging T1, T2 or T3
•7. Clinical node staging cN0 or cN1

•Current participant exclusion criteria as of 21/08/2024:
•1. Patients diagnosed with pure non-invasive breast cancer (e.g. DCIS) or with non-TNBC invasive subtypes,
•2. Patients diagnosed with distant metastatic disease at the time of primary breast cancer diagnosis
•3. Inability to provide informed written consent
•Previous participant exclusion criteria:
•1. Patients diagnosed with pure non-invasive breast cancer (e.g. DCIS) or with non-TNBC invasive subtypes (e.g. luminal/HER2 positive)
•2. Patients diagnosed with breast cancer locoregional recurrence (i.e. previous history of primary breast cancer)
•3. Patients diagnosed with distant metastatic disease at the time of primary breast cancer diagnosis
•4. Inability to provide informed written consent
•5. Patients with inflammatory breast cancer
•6. Tumour staging T4
•7. Clinical node staging N2 and N3

发起方

niversity of Leeds